Plesner, T;
Arkenau, HT;
Gay, F;
Minnema, MC;
Boccadoro, M;
Moreau, P;
Cavenagh, J;
... Richardson, PG; + view all
(2019)
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
British Journal of Haematology
, 186
(3)
e35-e39.
10.1111/bjh.15879.
Preview |
Text
Arkenau_BJHaematol 2018 Plesner Manuscript.pdf - Accepted Version Download (380kB) | Preview |
| Type: | Article |
|---|---|
| Title: | Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bjh.15879 |
| Publisher version: | https://doi.org/10.1111/bjh.15879 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | daratumumab, monoclonal antibody, multiple myeloma, relapsed/refractory multiple myeloma, plasma cell disorders |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10073407 |
Archive Staff Only
 |
View Item |
